Bimatoprost Versus Travoprost at Cairo University

This study has been completed.
Sponsor:
Information provided by:
Cairo University
ClinicalTrials.gov Identifier:
NCT01092273
First received: March 23, 2010
Last updated: NA
Last verified: January 2008
History: No changes posted
  Purpose

Bimatoprost has been shown to provide effective IOP lowering in patients of all races. Conversely, travoprost has been shown to be more effective in black patients than in Caucasians in some studies. However, Noecker et al 2004 compared bimatoprost with travoprost in African-Americans with glaucoma or OHT, and found that bimatoprost was more likely than travoprost to achieve target pressure at 3 months.

These racial differences in efficacy of these medications warrant further investigations. The investigators study aim to compare the IOP-lowering efficacies of bimatoprost and travoprost in an Egyptian population with primary open-angle glaucoma (OAG) or ocular hypertension (OHT).


Condition
Glaucoma
Ocular Hypertension

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Bimatoprost Versus Travoprost in an Egyptian Population: A Hospital-Based Prospective Randomized Study.

Resource links provided by NLM:


Further study details as provided by Cairo University:

Primary Outcome Measures:
  • Percentage of intraocular pressure lowering of bimatoprost versus travoprost.

Secondary Outcome Measures:
  • Rate of development of complications.

Groups/Cohorts
Bimatoprost versus Travoprost

  Eligibility

Ages Eligible for Study:   20 Years to 72 Years
Genders Eligible for Study:   Both
Sampling Method:   Non-Probability Sample
Study Population

Hospital Based Study at Cairo University and Al Nour Eye Hospital

Criteria

Inclusion Criteria:

  • Glaucoma and Ocular Hypertension

Exclusion Criteria:

  • Any ocular disease or medication that may raise the intraocular pressure.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01092273

Locations
Egypt
Cairo University
Cairo, Egypt, 11431
Sponsors and Collaborators
Cairo University
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT01092273     History of Changes
Other Study ID Numbers: Prostaglandins-Cairo-1A
Study First Received: March 23, 2010
Last Updated: March 23, 2010
Health Authority: Egypt:Al Nour Eye Hospital Medical Committee

Keywords provided by Cairo University:
Glaucoma and Ocular Hypertension

Additional relevant MeSH terms:
Glaucoma
Hypertension
Ocular Hypertension
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
Travoprost
Bimatoprost
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 28, 2014